Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
-
Review Meta Analysis
Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis.
The addition of Rituximab to standard chemotherapy (C) has been reported to improve the end of treatment outcome in non-Hodgkin lymphoma (NHL) patients. Nevertheless, rituximab has been associated with hepatitis B virus reactivation (HBV-R). ⋯ Rituximab therapy may increase the risk of developing HBV-R in NHL patients with HBcAb(+).